Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19933823 | 0.92 | KDM4E (0.43) | KDM4EALDH1A1 | |
| SCHEMBL19933882 | 0.90 | MAPK14 (0.44) | PTGS2 | |
| SCHEMBL19933816 | 0.86 | — | — | |
| SCHEMBL19927471 | 0.86 | PTGS2 (0.56) | CDC7PTGS2MGAMAMY1AGAA | |
| SCHEMBL19933936 | 0.83 | MEN1 (0.47) | — | |
| SCHEMBL19933959 | 0.83 | TP53 (0.52) | CDC7PTGS2MGAMAMY1AGAA | |
| SCHEMBL13307632 | 0.83 | MAPT (0.55) | CDC7PTGS2GAAL3MBTL1 | |
| SCHEMBL19933957 | 0.80 | KDM4E (0.41) | KDM4EALDH1A1 | |
| SCHEMBL19933826 | 0.78 | HSP90AA1 (0.40) | KDM4EALDH1A1 | |
| SCHEMBL19933952 | 0.78 | MAPK14 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793544-B2 | Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2020-10-06 | — | — | US | disclosed |
| US-20190202804-A1 | DISUBSTITUTED AND TRISUBSTITUTED 1,2,3-TRIAZOLES AS WNT INHIBITORS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2019-07-04 | — | — | US | disclosed |
| WO-2018045182-A1 | DISUBSTITUTED AND TRISUBTITUTED 1,2,3-TRIAZOLES AS WNT INHIBITORS | THE BOARD OF REGENTS OF HTE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190202804-A1 | DISUBSTITUTED AND TRISUBSTITUTED 1,2,3-TRIAZOLES AS WNT INHIBITORS | WNT1, WNT3, WNT3A | CDC7 332/4885PTGS2 1938/4885MGAM 3283/4885 |
| US-10793544-B2 | Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors | WNT1, WNT3, WNT3A | CDC7 332/4885PTGS2 1938/4885MGAM 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.